OTIC News and Press, Otonomy Inc. From 02/22/21

Gainers: ReTo Eco-Solutions (RETO) +93%.Celsion (CLSN) +62%.Rodgers Silicon Valley Acquisition (RSVA) +49%.Taoping (TAOP) +44%.RealNetworks (RNWK) +32%.Cooper Tire & Rubber (CTB) +30%.MICT (MICT) +26%.Conformis (CFMS) +26%.ATIF Holdings (ATIF) +25%.Vuzix (VUZI) +23%.Losers:...

Gainers: Celsion (CLSN) +54%, SunLink Health Systems (SSY) +27%, Citius Pharmaceuticals (CTXR) +26%, Can-Fite BioPharma (CANF) +19%, Aesthetic Medical International Holdings Group (AIH) +18%.Losers: Otonomy (OTIC) -43%, Brainstorm Cell Th...

Otonomy (OTIC) -51% after Otividex fails late-stage Ménière’s disease study.Ebix (EBIX) -32% as auditor resigns after flagging material weakness.Energous (WATT) -20%.MoneyGram International (MGI) -17% on Q4 earnings.Petroleo Brasileiro S.A. - Petrobra...

Otonomy (OTIC) has lost ~50.3% in the premarket after the announcement of the clinical trial failure for OTIVIDEX in patients with Ménière’s disease.Based on topline results, the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’...

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s diseas...

Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%. For further details see: PETS, IMUX, EVGN and OTIC among after-hours movers

Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q4 2020 Earnings Call Feb 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q4 2020 Earnings Call Transcript

Otonomy, Inc. (OTIC) Q4 2020 Earnings Conference Call February 11, 2021 16:30 ET Company Participants Robert Uhl - Investor Relations David Weber - President and Chief Executive Officer Paul Cayer - Chief Financial and Business Officer Conference Call Participants Ken Cacciatore - Cowen &...

OTIVIDEX ® Phase 3 trial results in Ménière’s disease expected by end of February OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 OTO-413 Phase 1/...

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corpo...